Weight Gain Common in Young Women After Breast Reduction Surgery
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Feb. 6, 2025 -- Many young women gain weight in the years after breast reduction surgery, according to a study published online in the February issue of Plastic and Reconstructive Surgery.
William N. Doyle Jr., from the University of South Florida Morsani College of Medicine in Tampa, and colleagues examined change in weight and body mass index (BMI) in adolescent women (aged younger than 21 years) following reduction mammaplasty. The analysis included 56 patients with weight measurements during a median 46.0 months of follow-up.
The researchers found that only 22 patients (39.3 percent) experienced a decrease in BMI at final follow-up compared with baseline. At two-, three-, and five-year visits and at final postoperative follow-up visits, patients classified as having a healthy weight preoperatively (BMI, 18.5 to 24.9 kg/m2) experienced a significant increase in BMI versus baseline. In contrast, patients classified as having overweight (BMI, 25.0 to 29.99 kg/m2) or obesity (≥30 kg/m2) did not experience significant BMI change at final postoperative follow-up.
"BMI and weight trended upward postoperatively regardless of BMI classification," the authors write. "Reduction mammaplasty alone is not sufficient to stimulate weight loss. Healthy lifestyle changes should be encouraged to help prevent weight gain in adolescent women following reduction mammaplasty."
One author disclosed receiving royalties for textbook authorship from Thieme Publishing.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-02-07 06:00
Read more

- FDA Announces 'Operation Stork Speed' to Improve Infant Formula
- FDA Warns of Rising Injuries From Misuse of Laughing Gas
- FDA OKs Amvuttra To Treat Heart Conditions
- Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
- Tonsil Removal Helps Kids With Snoring/Sleep Apnea
- Trump Administration To Cut 10,000 Health and Human Services Jobs
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions